 |
 |

Reduction in Blood Pressure With StatinsResults From the UCSD Statin Study, a Randomized Trial
Beatrice A. Golomb, MD, PhD;
Joel E. Dimsdale, MD;
Halbert L. White, PhD;
Janis B. Ritchie, BSN;
Michael H. Criqui, MD, MPH
Arch Intern Med. 2008;168(7):721-727.
Background Some studies have suggested reductions in blood pressure (BP)with statin treatment, particularly in persons with hypertension. Randomized trial evidence is limited.
Methods We performed a randomized, double-blind, placebo-controlled trial with equal allocation to simvastatin, 20 mg; pravastatin sodium,40 mg; or placebo for 6 months. Nine hundred seventy-three men and women without known cardiovascular disease or diabetes mellitus, with low-density lipoprotein cholesterol screening levels of 115 to 190mg/dL, had assessment of systolic and diastolic BP (SBP and DBP, respectively). Blood pressure values were compared for placebo vs statins by intention-to-treat (ITT) analysis. Additional analyses were performed that (1) were confined to subjects with neither high baseline BP (SBP >140 mm Hg or DBP >90mm Hg) nor receiving BP medications, to exclude groups in whom BP medications or medication changes may have influenced results, and (2) separately evaluated simvastatin and pravastatin (vs placebo). The time course of BP changes after statin initiation and the effect of stopping statins on BP were examined.
Results Statins modestly but significantly reduced BP relative to placebo,by 2.2 mm Hg for SBP (P = .02) and 2.4mm Hg for DBP (P < .001) in ITT analysis.Blood pressure reductions ranged from 2.4 to 2.8 mm Hg for both SBP and DBP with both simvastatin and pravastatin, in those subjects with full follow-up, and without potential for influence by BP medications (ie, neither receiving nor meriting BP medications).
Conclusions Reductions in SBP and DBP occurred with hydrophilic and lipophilic statins and extended to normotensive subjects. These modest effects may contribute to the reduced risk of stroke and cardiovascular events reported on statins.
Trial Registration clinicaltrials.gov Identifier: NCT00330980
Author Affiliations: Departments of Medicine (Drs Golomb and Criqui and Ms Ritchie), Family and Preventive Medicine (Drs Golomb and Criqui), Psychiatry (Dr Dimsdale), and Economics (Dr White), University of California, San Diego, La Jolla.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT)
Manisty et al.
Hypertension 2009;54:1009-1013.
ABSTRACT
| FULL TEXT
Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat
DeMarco et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;297:H1128-H1139.
ABSTRACT
| FULL TEXT
Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats
Elewa et al.
J. Pharmacol. Exp. Ther. 2009;330:532-540.
ABSTRACT
| FULL TEXT
Atorvastatin Prevents Angiotensin II-Induced Vascular Remodeling and Oxidative Stress
Briones et al.
Hypertension 2009;54:142-149.
ABSTRACT
| FULL TEXT
Response to Combination Treatment to Prevent Atherosclerosis
Kushiro
Hypertension 2009;54:e11-e11.
FULL TEXT
Statins, Central Blood Pressure, and Blood Pressure Amplification
Safar et al.
Circulation 2009;119:9-12.
FULL TEXT
Statins and Blood Pressure
Trompet et al.
Arch Intern Med 2008;168:2383-2383.
FULL TEXT
|